Skip to main content

Isis Extends Antisense Drug Discovery Collaboration With Lilly

NEW YORK, May 6 (GenomeWeb News) - Isis Pharmaceuticals announced today that it is extending its collaboration with Eli Lilly to develop antisense-based cancer therapeutics.

 

Under the collaboration, which was originally forged in June 2002, the companies will continue to characterize and develop RNaseH, siRNA, and splicing modulating inhibitors as potential treatments, Isis said. In addition, the companies will explore the use of RNA-directed technology to find potential anticancer drug targets.

 

Financial terms of the extension were not disclosed.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.